AUXILIUM PHARMACEUTICALS (Stock Symbol: AUXL)
AUXL- Stock Profile
| Tweet |
| Company Name: | AUXILIUM PHARMACEUTICALS |
| Stock Ticker (Symbol): | AUXL |
| Traded Exchange: | NASDAQ Stock Exchange |
| Average Traded Price: | $15.10 |
| Average Daily Traded Volume: | 1,151,500 |
| Started to Trade on: | Monday, July 26, 2004 |
AUXILIUM PHARMACEUTICALS Profile
Auxilium Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company primarily in the United States. It focuses on developing and marketing products to urologists, endocrinologists, primary care physicians, hand surgeons, and rheumatologists, as well as to orthopedic, general, and plastic surgeons. The company markets XIAFLEX (collagenase clostridium histolyticum), an injectable collagenase enzyme for the treatment of adult Dupuytren's contracture; and Testim, a topical 1% testosterone gel for the treatment of hypogonadism. The company's clinical development products include XIAFLEX that is in Phase III clinical trials for the treatment of Peyronie's disease, as well as in Phase II clinical trials for the treatment of Adhesive Capsulitis. In addition, it has rights to develop other products for the treatment of pain, urologic disease, and hormone replacement using its transmucosal film delivery system. The company has a strategic alliance with Asahi Kasei Pharma Corporation for the development, commercialization, and supply of XIAFLEX, a biologic for the treatment of Dupuytren's contracture and Peyronie's disease. Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania.
| AUXL Charts | AUXL Quotes | AUXL Analysis | AUXL Price Calculators | AUXL Volume Calculators | AUXL Volatility Calculators |
You are logged Out of the Members' Area
To have access to real-time quotes, charts, trading signals and fresh market outlook you have to be logged in:
Not a member yet?
Click here to become a full member of MarketVolume® and enjoy the benefits of a feature rich
market timing system!
No, Thanks, I would like to check the website first.